Kenneth Olivier, MD, MPH

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Mannkind Corporation
    Topic:
    Nontuberculous mycobacteria
    Date added:
    02/08/2026
    Date updated:
    02/08/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Spero Therapeutics
    Topic:
    Nontuberculous mycobacteria
    Date added:
    02/08/2026
    Date updated:
    02/08/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Paratek Pharma
    Topic:
    Nontuberculous mycobacteria
    Date added:
    02/08/2026
    Date updated:
    02/08/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Insmed, Inc
    Topic:
    Bronchiectasis, Nontuberculous mycobacteria
    Date added:
    02/08/2026
    Date updated:
    02/08/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    AN2 Therapeutics
    Topic:
    Nontuberculous mycobacteria
    Date added:
    02/08/2026
    Date updated:
    02/08/2026
  • Attribution:
    Self
    Type of financial relationship:
    Contracted Research
    Ineligible company:
    Verona Pharma/Merck
    Topic:
    Bronchiectasis
    Date added:
    02/08/2026
    Date updated:
    02/08/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Beyond Air
    Topic:
    Nontuberculous mycobacteria
    Date added:
    02/08/2026
    Date updated:
    02/08/2026
  • Attribution:
    Self
    Type of financial relationship:
    Contracted Research
    Ineligible company:
    ReCode Therapeutics
    Topic:
    Primary ciliary dyskinesia
    Date added:
    02/08/2026
    Date updated:
    02/08/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    CSL Behring
    Topic:
    Bronchiectasis
    Date added:
    02/08/2026
    Date updated:
    02/08/2026
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    PCD Foundation
    Topic:
    Primary ciliary dyskinesia
    Date added:
    02/08/2026
    Date updated:
    02/08/2026

Pages

Return to March 13, 2026 32nd Advances in Pulmonary and Critical Care Medicine - Hybrid Conference